Latigo Biotherapeutics https://validator.w3.org/feed/docs/rss2.html Latigo Biotherapeutics Appoints Neha Krishnamohan as Chief Financial Officer and Chief Business Officer media home Anil Chhettry, Ph.D. Polina German, Pharm.D. Neil Singla, M.D. Sabrina Nieder Becky Baggett Nima Farzan Kevin Raidy Cynthia Voong Ben Vaughn Sarah Popham Mike Kaufman, Ph.D. Caroline Dougherty Holly Carlisle, Ph.D. Bryan Moyer, Ph.D. Nima Farzan Julia Chapman contact us science Deborah Palestrant, Ph.D., M.B.A. Latigo Biotherapeutics Debuts with $135 Million Series A Financing to Develop Non-Opioid Pain Medicines Latigo Biotherapeutics Doses First Participant in Phase 1 Clinical Trial of LTG-305 for Non-Opioid Treatment of Pain careers Latigo Biotherapeutics Announces Positive Phase 1 Data for 
Lead Non-Opioid Pain Medicine Candidate and Appoints Neil Singla, M.D., Chief Medical Officer Latigo Biotherapeutics Appoints Industry Veteran Timothy P. Walbert as Board Chair Timothy P. Walbert privacy policy Beth Seidenberg, M.D. Pharmacologic Characterization of LTGO-<sub>33</sub>, a Selective Small Molecule Inhibitor of the Voltage-Gated Sodium Channel Na<sub>V</sub>1.8 with a Unique Mechanism of Action Latigo Biotherapeutics Appoints Nima Farzan as Chief Executive Officer, Positioning Company for Rapid Growth team Latigo Biotherapeutics Granted FDA Fast Track Designation for LTG-001, Potential Best-in-Class Na<sub>v</sub>1.8 Inhibitor for the Non-Opioid Treatment of Acute Pain Terms of Use Jim Tananbaum, M.D. Latigo Biotherapeutics Appoints Tim Lugo as Chief Financial Officer and Adds Beth Seidenberg and Jim Tananbaum to Board of Directors Neha Krishnamohan Latigo Biotherapeutics Closes $150 Million in Series B Financing to Advance Non-Opioid Pain Therapeutics